Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Exicure, Inc. Common Stock

XCUR

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Last trade $1.08
Day change +$0.01 (+0.93%)
Day range $1.01 – $1.15
Volume 18,598
Market cap $7M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$7M
Price / earnings
—
Price / book
7.17×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.74×

Profitability

Earnings per share
-$1.27
Return on assets
-72.69%
Return on equity
-847.9%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.56×
Quick ratio
0.56×
Cash ratio
0.41×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XCUR, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$889K$1.29M$1.6M$1.5M$1.51M$2.22M$1.44M$1.43M
Research and development$174K$312K$655K$888K$935K$808K$0$0
Total operating expenses$1.06M$1.6M-$3.72M$2.39M$2.45M-$2.95M$7.59M$2.57M
Operating income-$1.06M-$1.6M$3.72M-$2.39M-$2.45M$2.95M-$7.59M-$2.57M
Interest expense$0$0-$1K$0$0$0$0-$12K
Income before taxes-$1.12M-$1.83M-$3.53M-$2.44M-$2.62M$3.01M-$7.18M-$1.08M
Income taxes$0$0-$634K$0$0$0$0$8K
Net income-$1.12M-$1.83M-$2.9M-$2.44M-$2.62M$3.01M-$7.18M-$1.09M
Net income attributable to common shareholders-$1.12M-$1.83M-$2.9M-$2.44M-$2.62M$3.01M-$7.18M-$1.09M
EBITDA-$1.02M-$1.55M-$2.23M-$2.31M-$2.38M-$2.96M-$1.44M-$1.43M
Basic earnings per share-$0.18-$0.29-$0.45-$0.39-$0.41$0.49-$2.55-$0.57
Diluted earnings per share-$0.18-$0.29-$0.46-$0.39-$0.41$0.49-$2.55-$0.57

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion

Exicure announced the sale of its GPC-100 (burixafor) program assets to South Korean company GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion). The transaction includes clinical data, intellectual property, and related materials from the Phase 2 clinical trial completed in January 2026. GPCRT will assume future milestone and royalty obligations, while Exicure retains liabilities incurred before September 1, 2026. The sale is part of Exicure's strategic alternatives evaluation to maximize stockholder value.

GlobeNewswire Inc.

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure, Inc. (Nasdaq: XCUR) received a notification from Nasdaq on May 28, 2026 for non-compliance with listing rules due to delayed filing of its Q1 2026 Form 10-Q. The delay was attributed to changes in financial reporting personnel and procedures. The company filed the report on May 29, 2026 and believes it has regained compliance.

GlobeNewswire Inc.

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure, Inc. announced a co-development agreement with Korea-based Adbiotech to explore combination therapies using Burixafor (GPC-100) across multiple therapeutic areas including sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech will conduct in vivo studies while Exicure provides Burixafor and leads clinical strategy. The collaboration aims to advance selected programs into IND-enabling studies and clinical trials with future funding to be secured.

GlobeNewswire Inc.

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure announced publication of Phase 2 data for burixafor, a CXCR4 inhibitor, demonstrating rapid stem cell mobilization in multiple myeloma and lymphoma patients. The study showed 92% of participants met primary endpoints with same-day cell collection capability, significantly faster than currently approved alternatives. The drug was well-tolerated with minimal adverse events and showed potential applications beyond transplant including gene therapy and CAR-T approaches.

GlobeNewswire Inc.

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure, Inc. announced it will present positive Phase 2 trial data for burixafor at the 2026 Tandem Meetings in Salt Lake City. The trial evaluated burixafor's ability to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous transplantation, with 89.7% of patients meeting the primary endpoint and demonstrating a favorable safety profile with same-day administration.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 28, 20241-for-5reverse split
Jun 30, 20221-for-30reverse split